MAGNIFY: A phase IIIb trial shows promising efficacy in the treatment of relapsed/refractory, indolent non-Hodgkin lymphoma patients with lenalidomide in combination with rituximab (R2)

被引：0
|
作者：
Burchardt, A. [1 ]
Andorsky, D. J. [2 ]
Schmidt, B. [3 ]
La Rosee, P. [4 ]
Graeven, U. [5 ]
Czuczman, M. [6 ]
Llorente, M. [6 ]
Li, J. [6 ]
Sharman, J. [7 ]
机构：
[1] Justus Liebig Univ Giessen, Giessen, Germany
[2] US Oncol Res, Rocky Mt Canc Ctr, Boulder, CO USA
[3] Hamatoonkol Uberortliche Gemeinschaftspraxis Pasi, Munich, Germany
[4] Schwarzwald Baar Klinikum, Klin Innere Med 2, Villingen Schwenningen, Germany
[5] Kliniken Maria Hilf GmbH, Klin Hamatol Onkol & Gastroenterol, Monchengladbach, Germany
[6] Celgene Corp, Summit, NJ USA
[7] US Oncol Res, Willamette Valley Canc Inst & Res Ctr, Eugene, OR USA
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2019年 / 42卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V608
引用
收藏
页码：160 / 161
页数：2
相关论文
共 50 条
  • [41] A phase I trial of bortezomib in combination with everolimus for treatment of relapsed/refractory non-Hodgkin lymphoma
    Hill, Brian T.
    Smith, Mitchell R.
    Shelley, Meredeth
    Jagadeesh, Deepa
    Dean, Robert M.
    Pohlman, Brad
    Sweetenham, John W.
    Bolwell, Brian J.
    Smith, Stephen D.
    LEUKEMIA & LYMPHOMA, 2018, 59 (03) : 690 - 694
  • [42] Response rate to lenalidomide plus rituximab (R2) as independent of number of prior lines of therapy: Interim analysis of initial phase of MAGNIFY phase IIIb study of R2 followed by maintenance in relapsed/refractory indolent NHL.
    Andorsky, David
    Coleman, Morton
    Yacoub, Abdulraheem
    Melear, Jason M.
    Brooks, Heather Dawn
    Fanning, Suzanne R.
    Kolibaba, Kathryn S.
    Lansigan, Frederick
    Reynolds, Chris
    Li, Jiahui
    Liu, Dongfang
    Llorente, Mary
    Ricker, Justin L.
    Sharman, Jeff Porter
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [43] Introduction: Treatment of patients with rituximab-refractory indolent non-hodgkin's lymphoma
    Gregory, Stephanie A.
    SEMINARS IN HEMATOLOGY, 2007, 44 (03) : S1 - S1
  • [44] Five-Year Results and Overall Survival Update from the Phase 3 Randomized Study Augment: Lenalidomide Plus Rituximab (R2) Vs Rituximab Plus Placebo in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
    Leonard, John P.
    Trneny, Marek
    Offner, Fritz
    Mayer, Jiri
    Zhang, Huilai
    Nowakowski, Grzegorz S.
    Scheinberg, Phillip
    Gkasiamis, Argyrios
    Mikita-Geoffroy, Joanna
    Rowe, Everton
    Gribben, John G.
    BLOOD, 2022, 140
  • [45] Patients with Relapsed/Refractory Marginal Zone Lymphoma in the MAGNIFY Phase IIIb Interim Analysis of Induction R2 Followed By Maintenance
    Coleman, Morton
    Andorsky, David Jacob
    Yacoub, Abdulraheem
    Melear, Jason M.
    Fanning, Suzanne R.
    Kolibaba, Kathryn S.
    Lansigan, Frederick
    Reynolds, Christopher M.
    Nowakowski, Grzegorz S.
    Gharibo, Mecide
    Ahn, Erin
    Li, Ju
    Rummel, Mathias J.
    Sharman, Jeff P.
    BLOOD, 2020, 136
  • [46] Magrolimab in Combination With Rituximab in Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma: 3-Year Follow-up Results From a Phase 1/2 Trial
    Amitkumar, Mehta
    Leslie, Popplewell
    Collins, Graham P.
    Sonali, Smith
    Ian, Flinn
    Bartlett, Nancy S.
    Nilanjan, Ghosh
    Carolc, O'Hear
    Yanan, Huo
    Bertha, Villa
    Indu, Lal
    Ranjana, Advani
    Mark, Roschewski
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 : S21 - S21
  • [47] Subgroup Analyses of Elderly Patients Aged ≥ 70 Years in AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R2) vs Rituximab Plus Placebo (R-Placebo) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)
    Trneny, Marek
    Leonard, John P.
    Zhang, Huilai
    Nowakowski, Grzegorz
    Izutsu, Koji
    Fowler, Nathan H.
    Thieblemont, Catherine
    Zinzani, Pier Luigi
    Kalambakas, Stacey
    Czuczman, Myron
    Fustier, Pierre
    Wu, Chengqing
    Gribben, John G.
    BLOOD, 2019, 134
  • [48] Subgroup analyses of elderly patients aged ≥ 70 years in MAGNIFY: A phase 3b interim analysis of induction R2 followed by maintenance in Relapsed/Refractory indolent non-Hodgkin lymphoma
    Rummel, M. J.
    Lansigan, F.
    Andorsky, D. J.
    Coleman, M.
    Yacoub, A.
    Melear, J. M.
    Fanning, S. R.
    Kolibaba, K. S.
    Reynolds, C.
    Nowakowski, G.
    Gharibo, M.
    Ahn, E.
    Li, J.
    Sharman, J. P.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 154 - 154
  • [49] Phase I/II Trial of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)
    Kallam, Avyakta
    Meza, Jane
    Bierman, Philip
    Lunning, Matthew A.
    Bociek, R. Gregory
    Armitage, James Olen
    Vose, Julie M.
    BLOOD, 2017, 130
  • [50] Phase 3 Trial of Subcutaneous Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Vs R2 Among Patients with Relapsed or Refractory Follicular Lymphoma (EPCORE FL-1)
    Falchi, Lorenzo
    Morschhauser, Franck
    Gribben, John G.
    Huang, Huiqiang
    Minh Dinh
    Conlon, Rebekah
    Chen, Xiaorong
    Elliot, Brian
    Seymour, John F.
    BLOOD, 2022, 140 : 9338 - 9339
12345